Frequently Asked Questions

Digistain® Breast measures protein-level biomarkers linked to the growth and spread of cancer cells. Using infrared spectrometry, it captures a unique spectral signature from each biopsy, generating over 10,000 data points tailored to each woman’s biology. This data is then analysed using artificial intelligence to accurately determine the 10-year risk of breast cancer recurrence.

Personalised, also known as Precision Medicine tailors medical decisions to reflect your unique characteristics. Unlike generalised approaches, it focuses on your specific breast cancer profile, ensuring treatment options align with your individual circumstances, goals, and life aspirations.

You may be eligible for the Digistain® Breast if you are medically eligible for chemotherapy and meet the following criteria:

  • Your breast cancer is hormone receptor-positive (HR+).
  • Your breast cancer is human epidermal growth factor receptor-negative (HER2-).
  • You have been recently diagnosed with stage I or II invasive breast cancer.
  • Your cancer has spread to up to 3 lymph nodes.

If you’re unsure whether Digistain® is right for you, consult your doctor for guidance.

Digistain® Breast delivers results within 24 hours of a sample’s arrival at our UK facilities. International courier delivery typically takes 48 to 72 hours.

Digistain® Breast has been clinically validated, demonstrating equivalent accuracy to traditional risk profiling methods in predicting breast cancer recurrence, recurrence-free survival, and overall survival at both 5 and 10 years. What sets Digistain® apart is its innovative new approach, delivering the same reliable outcomes faster and more affordably than ever before.

Digistain® Breast is reimbursed by leading global healthcare insurers, including BUPA, Healix, and WPA. Contact your insurance provider to check your coverage.

Patients are unable to order a test directly. A physician must send the requisition form along with the samples. 

Digistain® Breast is available globally and can be ordered by physicians anywhere. To learn more about ordering a test, consult your physician or contact us at support@digistain.co.uk.

HR+ stands for hormone receptor-positive, meaning breast cancer cells have receptors that bind to the hormones estrogen and progesterone. HR+ cancers may grow in response to these hormones, but they can often be treated with hormone therapies that block or reduce hormone levels in the blood.

HER2- stands for human epidermal growth factor receptor-negative, meaning the breast cancer cells do not produce excess amounts of the HER2 protein. HER2 is a protein that promotes cancer cell growth, so HER2- cancers typically grow more slowly and are less aggressive than HER2-positive cancers. Since HER2-targeted therapies are ineffective for HER2- cancers, treatment usually focuses on other options like hormone therapy or chemotherapy, depending on the cancer’s other characteristics.

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.